Cargando…
Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
The recent development of immunotherapy represents a significant breakthrough in cancer therapy. Several immunotherapies provide robust efficacy gains in a wide variety of cancers. However, in some patients the immune checkpoint blockade remains ineffective due to poor therapeutic response and tumor...
Autores principales: | Rupp, Tristan, Genest, Laurie, Babin, David, Legrand, Christophe, Hunault, Marion, Froget, Guillaume, Castagné, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961218/ https://www.ncbi.nlm.nih.gov/pubmed/35339889 http://dx.doi.org/10.1016/j.tranon.2022.101405 |
Ejemplares similares
-
A Face-To-Face Comparison of Tumor Chicken Chorioallantoic Membrane (TCAM) In Ovo with Murine Models for Early Evaluation of Cancer Therapy and Early Drug Toxicity
por: Rupp, Tristan, et al.
Publicado: (2022) -
Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models
por: Rupp, Tristan, et al.
Publicado: (2020) -
Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models
por: Davy, Mélodie, et al.
Publicado: (2023) -
Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models
por: Rupp, Tristan, et al.
Publicado: (2022) -
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)